The presenter highlights that Neurocrine is holding up well despite broader market challenges, indicating a positive outlook. The mention of its recent earnings performance as a catalyst also supports a bullish stance.
The presenter highlights strong fundamentals, including significant revenue from a key drug and positive earnings revisions, indicating a bullish outlook for Neurocrine Biosciences.
No conviction history yet for this window.
First in this window: Zacks Investment Research · Jun 29, 2026
| Channel | Mentions | Weight | Stance |
|---|---|---|---|
| CInvestor's Business Daily180k subs | 1 | 16.75 | BULL |
| CZacks Investment Research70k subs | 1 | 16.75 | BULL |
| Video | Channel | Published | Weight |
|---|---|---|---|
| Monday Gap Up Doesn’t Hold; Neurocrine Bio, Rush Street, Burlington In Focus | Stock Market TodayWatch on YouTube ↗ | Investor's Business Daily | Jul 20, 2026 | 16.75 |
| Top Stock Picks for Week of June 29, 2026Watch on YouTube ↗ | Zacks Investment Research | Jun 29, 2026 | 16.75 |